glioma
Conditions
Interventions
Experimental group:60Gy radiotherapy combined with temozolomide synchronous and adjuvant chemotherapy
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. voluntarily participate in the study and sign the informed consent form. 2. age >=18 years, regardless of gender. 3. complete or near-total resection (>=90%) of newly diagnosed supratentorial tumors. 4. histologically confirmed grade 2 or 3 astrocytoma. 5. molecular pathology confirmed IDH mutation with CDKN2A/B deletion and no combined 1p/19q deletion. 6. synchronous radiotherapy was started within 8 weeks (= 100*109/L; absolute neutrophil count >= 1.5*10^9/L or white blood cell count >= 3.0*10^9/L; hemoglobin >= 90g/L; blood biochemistry: portal aminotransferase (AST) = 60. 9. subjects of childbearing potential are willing to use contraception during the study period.
Exclusion criteria
Exclusion criteria: 1. recurrence or intracranial or spinal metastases of glioma or other malignant tumors outside the center 2. have not undergone craniotomy for resection or the extent of resection has not reached major resection (<= 90%) 3. have received any previous antitumor treatment other than herbal therapy, including surgical treatment, chemotherapy (except temozolomide given postoperatively), radiotherapy, targeted drugs, immunotherapy, etc. 4. the presence of uncontrollable infection, uncontrollable epilepsy and/or hypertension and/or hyperglycemia 5. presence of human immunodeficiency virus (HIV) infection or active hepatitis B (HBsAg positive and HBV-DNA positive) infection or hepatitis C (HCV antibody positive) infection 6. active hemorrhage and/or inability to perform cranial CT or MRI prior to enrollment as detected by cranial CT or MRI scan 7. history of decompensated heart failure (NYHA class III and IV), unstable angina pectoris, acute myocardial infarction, persistent and clinically significant arrhythmia within three months prior to enrollment. 8. known hypersensitivity to temozolomide or its analogs or any component of the prescription 9. inability to cooperate with completion of radiotherapy. 10. other reasons, as judged by the investigator, for not being suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Countries
China
Contacts
Public ContactXiaoguang Qiu
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed